論文 - 詳細
| RRC ID | 18593 |
|---|---|
| 著者 | Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E. |
| タイトル | Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. |
| ジャーナル | Int J Cancer |
| Abstract |
The spontaneous immune responses against XAGE-1b (GAGED2a) were analyzed in non-small cell lung cancer (NSCLC) patients. An antibody response against XAGE-1b (GAGED2a) was observed in 10% (20/200) of NSCLC patients and in 19% (13/69) of stage IIIB/IV lung adenocarcinoma patients. A CD4 T-cell response was detected in 88% (14/16) and a CD8 T-cell response in 67% (6/9) in the XAGE-1b (GAGED2a) antibody-positive patients examined. Frequent antibody responses and CD4 and CD8 T-cell responses in XAGE-1b (GAGED2a) antibody-positive patients indicate the strong immunogenicity of the XAGE-1b (GAGED2a) antigen in NSCLC patients. We established T-cell clones from PBMCs of antibody-positive patients and determined the DRB1*04:05-restricted XAGE-1b (GAGED2a) 18-31 peptide (14-mer) as a CD4 T cell epitope and the A*02:06-restricted XAGE-1b (GAGED2a) 21-29 peptide (9-mer) as a CD8 T cell epitope. As for peptide recognition, CD4 and CD8 T-cell clones responded to naturally processed antigen. The CD4 T-cell clone recognized DCs pulsed with the synthetic protein or a lysate from XAGE-1b-transfected 293T cells. The CD8 T-cell clone showed cytotoxicity against a tumor expressing XAGE-1b (GAGED2a) and the appropriate HLA class I allele. These findings establish XAGE-1b (GAGED2a) as a promising target for a lung cancer vaccine. |
| 巻・号 | 131(5) |
| ページ | E649-58 |
| 公開日 | 2012-9-1 |
| DOI | 10.1002/ijc.27359 |
| PMID | 22109656 |
| MeSH | Adenocarcinoma / genetics Adenocarcinoma / immunology Adenocarcinoma / metabolism Antibodies, Neoplasm / blood* Antibodies, Neoplasm / immunology Antigens, Neoplasm / genetics Antigens, Neoplasm / immunology* Antigens, Neoplasm / metabolism Apoptosis Blotting, Western CD4-Positive T-Lymphocytes / immunology* CD4-Positive T-Lymphocytes / metabolism CD4-Positive T-Lymphocytes / pathology CD8-Positive T-Lymphocytes / immunology* CD8-Positive T-Lymphocytes / metabolism CD8-Positive T-Lymphocytes / pathology Carcinoma, Large Cell / genetics Carcinoma, Large Cell / immunology Carcinoma, Large Cell / metabolism Carcinoma, Non-Small-Cell Lung / genetics Carcinoma, Non-Small-Cell Lung / immunology* Carcinoma, Non-Small-Cell Lung / metabolism Carcinoma, Squamous Cell / genetics Carcinoma, Squamous Cell / immunology Carcinoma, Squamous Cell / metabolism Case-Control Studies Cell Proliferation Dendritic Cells / immunology Dendritic Cells / metabolism Dendritic Cells / pathology Enzyme-Linked Immunosorbent Assay Epitopes, T-Lymphocyte / immunology Epitopes, T-Lymphocyte / metabolism Humans Interferon-gamma / metabolism Lung / immunology Lung / metabolism Lung Neoplasms / genetics Lung Neoplasms / immunology* Lung Neoplasms / metabolism Neoplasm Staging Peptide Fragments / immunology Prognosis RNA, Messenger / genetics Real-Time Polymerase Chain Reaction Reverse Transcriptase Polymerase Chain Reaction Tumor Cells, Cultured |
| IF | 5.145 |
| 引用数 | 25 |
| WOS 分野 | ONCOLOGY |
| オルトメトリクス指標 |
オルトメトリクス指標項目
|
| 最多言及媒体 | Patent(IFI CLAIMS) |
| 各媒体での言及数の合計 | 12 |
| 過去6か月間でのオルトメトリクス指標の変動値 | 0.0 |
| リソース情報 | |
| ヒト・動物細胞 | 293T(RCB2202) RERF-LC-AI(RCB0444) |